Dr. Lal Pathlabs Ltd. (LALPATHLAB) Share Price Surges 6.11% Today

Dr. Lal Pathlabs Ltd. Share Price surged 6.11% today to Rs 1,864, with a market cap of Rs 29,448.93 crore.

Dr. Lal Pathlabs Ltd. Share Price experienced a significant surge today, rising by 6.11% to reach Rs 1,864. This notable increase in the share price highlights the stock’s performance in the market, with a market capitalisation of Rs 29,448.93 crore. The healthcare sector company has captured investor attention, as evidenced by the substantial price movement. The data confirms the price event but does not establish a company-specific catalyst for this rise. Investors and market participants are closely monitoring the stock’s performance, given its large-cap status and the substantial price gain recorded today.

Dr. Lal Pathlabs Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,864
Previous Close	Rs 1,756.7
Today's Change	+Rs 107.3 (+6.11%)
Day Open	Rs 1,797.3
Day High	Rs 1,893.65
Day Low	Rs 1,794.4
Current Volume (BSE)	70,093
BSE Traded Volume	70,093
NSE Traded Volume	17,08,933
Combined NSE + BSE Volume	17,79,026
Turnover	Rs 13.07 crore
Market Capitalisation	Rs 29,448.93 crore
Market Cap Category	Large Cap
Qualifying Threshold Cleared	3%

Today’s trading session saw Dr. Lal Pathlabs Ltd. opening at Rs 1,797.3, with the share price reaching a high of Rs 1,893.65 and a low of Rs 1,794.4. The stock closed at Rs 1,864, marking a day change of Rs 107.3, equivalent to a 6.11% increase. The total volume traded was 1,779,026 shares, with a turnover of Rs 13.07 crore. This volume indicates strong market participation, as the volume ratio is above 1, suggesting heightened trading activity compared to the average. Dr. Lal Pathlabs Ltd. falls under the Large Cap category, and today’s price rise of 6.11% significantly exceeds the qualifying threshold of 3% for this market-cap category. The substantial gain positions the stock as a top gainer in today’s market, attracting attention from investors and analysts alike.

Dr. Lal Pathlabs Ltd. Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 29,448.93 crore
P/E Ratio	31.07x
P/B Ratio	2.36x
ROE	29.2%
ROCE	27.13%

Dr. Lal Pathlabs Ltd. was valued at a P/E ratio of 31.07x, a P/B ratio of 2.36x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 29.2% and ROCE of 27.13%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Dr. Lal Pathlabs Ltd. boasts a market capitalisation of Rs 29,448.93 crore, reflecting its significant presence in the healthcare sector. The company’s P/E ratio stands at 31.07, while the P/B ratio is 2.36. These valuation metrics suggest that the stock is priced relatively higher compared to the sector’s median P/E of 20.79 and P/B of 1.89. The company’s return on equity (ROE) is an impressive 29.2%, and the return on capital employed (ROCE) is 27.13%, both of which are significantly above the sector’s median ROE of 10.69% and ROCE of 13.12%. These figures indicate strong profitability and efficient capital utilisation. The healthcare sector’s benchmark includes 203 companies, providing a comprehensive context for evaluating Dr. Lal Pathlabs Ltd.’s performance. The company’s robust financial metrics and market position contribute to its attractiveness among investors.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Companies in Benchmark	203
Company P/E Ratio	31.07x
Benchmark Median P/E	20.79x
Benchmark Average P/E	67.01x
Benchmark P/E Range	0x to 3,482.29x
Companies with P/E Data	203
Company P/B Ratio	2.36x
Benchmark Median P/B	1.89x
Company ROE	29.2%
Benchmark Median ROE	10.69%
Company ROCE	27.13%
Benchmark Median ROCE	13.12%
Company Market Capitalisation	Rs 29,448.93 crore
Benchmark Median Market Cap	Rs 130.49 crore

Dr. Lal Pathlabs Ltd. (LALPATHLAB) is classified under sector: Healthcare. The numerical benchmark uses 203 same sector companies from the supplied master-data set.

Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a P/E ratio of 31.07x, which is above the benchmark median of 20.79x, a difference of +49.45%. The benchmark contains 203 companies with P/E data, ranging from 0x to 3,482.29x. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a ROE of 29.2%, which is above the benchmark median of 10.69%, a difference of +173.15%. Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a ROCE of 27.13%, which is above the benchmark median of 13.12%, a difference of +106.78%.

Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Dr. Lal Pathlabs Ltd. operates within the healthcare sector, which comprises 203 companies. The sector’s P/E median is 20.79, with an average of 67.01, indicating a wide range of valuations. The company’s P/E ratio of 31.07 is above the sector median, suggesting a relatively higher valuation. The sector’s P/B median is 1.89, with an average of 2.78, while Dr. Lal Pathlabs Ltd.’s P/B ratio is 2.36, aligning closely with the sector average. The company’s ROE of 29.2% and ROCE of 27.13% are significantly higher than the sector medians of 10.69% and 13.12%, respectively, highlighting its superior profitability and operational efficiency. The healthcare sector’s market capitalisation range is broad, with Dr. Lal Pathlabs Ltd. positioned at the upper end, underscoring its large-cap status and strong market presence.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Morepen Laboratories Ltd.	MOREPENLAB	2,947.44	31.07	2.36	29.2	27.13
Dishman Carbogen Amcis Ltd.	DCAL	2,885.59	29.61	0.43	-2.89	-0.26
Kwality Pharmaceuticals Ltd.	KPL	2,881.37	42.78	8.71	28.21	26.35
Beta Drugs Ltd.	BETA	2,567.04	61.88	8.27	18.65	22.17
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,425.38	34.6	7	-2.6	16.92

Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a P/E ratio of 31.07x compared with the displayed peer median of 34.6x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 29.2% compares with a peer median of 18.65% across the companies shown in the table. ROCE stood at 27.13% versus the displayed peer median of 22.17%, providing a capital-efficiency comparison. Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a market capitalisation of Rs 29,448.93 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

In comparison to its peers, Dr. Lal Pathlabs Ltd. demonstrates competitive financial metrics. Morepen Laboratories Ltd. shares the same P/E and P/B ratios of 31.07 and 2.36, respectively, with a market cap of Rs 2,947.44 crore. Kwality Pharmaceuticals Ltd. has a higher P/E of 42.78 and a P/B of 8.71, with a market cap of Rs 2,881.37 crore. Beta Drugs Ltd. exhibits a P/E of 61.88 and a P/B of 8.27, with a market cap of Rs 2,567.04 crore. Dr. Agarwals Eye Hospital Ltd. has a P/E of 34.6 and a P/B of 7, with a market cap of Rs 2,425.38 crore. Dr. Lal Pathlabs Ltd.’s market cap of Rs 29,448.93 crore positions it as a leader among its peers, with strong ROE and ROCE metrics further enhancing its competitive edge.

Why Investors Are Watching Dr. Lal Pathlabs Ltd.

Investors are closely monitoring Dr. Lal Pathlabs Ltd. due to its significant price rise and strong financial metrics. The company’s large-cap status and robust profitability make it an attractive investment option.

• Price Action: Share price surged 6.11% today.
• Technical Position: Strong market participation with high volume.
• Fundamental Context: High ROE and ROCE compared to sector medians.
• Sector Positioning: Operates in the healthcare sector with a large market cap.

Investors should continue to monitor Dr. Lal Pathlabs Ltd.’s performance, particularly its ability to sustain profitability and market leadership in the healthcare sector.

About Dr. Lal Pathlabs Ltd.

Dr. Lal Pathlabs Ltd. is a leading diagnostic and healthcare services provider in India, offering a wide range of tests and services. The company operates a network of laboratories and patient service centers across the country, catering to a diverse clientele. Its comprehensive diagnostic services include pathology and radiology tests, making it a key player in the healthcare sector. Dr. Lal Pathlabs Ltd. is known for its commitment to quality and accuracy, leveraging advanced technology and skilled professionals to deliver reliable results. The company’s strong market presence and extensive service offerings position it as a trusted name in the industry.

Track Dr. Lal Pathlabs Ltd. Share Price on Univest

Use Dr. Lal Pathlabs Ltd. (LALPATHLAB) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors and market enthusiasts can track Dr. Lal Pathlabs Ltd. Share Price on Univest for live updates, technical indicators, fundamental ratios, and market insights. Univest provides comprehensive data, including shareholding patterns, 52-week levels, and sector performance, enabling users to make informed investment decisions.

Frequently Asked Questions

What was Dr. Lal Pathlabs Ltd.'s share price today?

Ans. Dr. Lal Pathlabs Ltd.'s share price today was Rs 1,864, marking a 6.11% increase from the previous close of Rs 1,756.7. The stock moved 6.11% during the session. The intraday range extended from Rs 1,794.4 to Rs 1,893.65.

What is Dr. Lal Pathlabs Ltd.'s market capitalisation?

Ans. Dr. Lal Pathlabs Ltd.'s market capitalisation is Rs 29,448.93 crore, reflecting its significant presence in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 31.07x.

What are Dr. Lal Pathlabs Ltd.'s valuation metrics?

Ans. Dr. Lal Pathlabs Ltd. has a P/E ratio of 31.07 and a P/B ratio of 2.36, indicating a relatively higher valuation compared to sector medians. The company trades at a P/E ratio of 31.07x.

How does Dr. Lal Pathlabs Ltd.'s ROE compare to the sector?

Ans. Dr. Lal Pathlabs Ltd.'s ROE is 29.2%, significantly higher than the sector median of 10.69%, showcasing strong profitability. ROE stands at 29.2%. ROCE stands at 27.13%. The relevant peer median ROE is 10.69%.

What is the sector context for Dr. Lal Pathlabs Ltd.?

Ans. Dr. Lal Pathlabs Ltd. operates in the healthcare sector, which includes 203 companies, with varying valuations and performance metrics. The stock belongs to the Healthcare sector. 203 comparable companies were included in the benchmark.

Who are Dr. Lal Pathlabs Ltd.'s peers?

Ans. Dr. Lal Pathlabs Ltd.'s peers include Morepen Laboratories Ltd., Kwality Pharmaceuticals Ltd., and Beta Drugs Ltd., among others. Comparable listed companies include Morepen Laboratories Ltd., Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd.

What is Dr. Lal Pathlabs Ltd.'s ROCE?

Ans. Dr. Lal Pathlabs Ltd.'s ROCE is 27.13%, indicating efficient capital utilisation and strong operational performance. ROE stands at 29.2%. ROCE stands at 27.13%. The relevant peer median ROE is 10.69%.

What is Dr. Lal Pathlabs Ltd.'s sector P/E median?

Ans. The healthcare sector's P/E median is 20.79, with Dr. Lal Pathlabs Ltd. having a higher P/E ratio of 31.07. The company trades at a P/E ratio of 31.07x. Its P/B ratio is 2.36x.